{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:02:12Z","timestamp":1753891332419,"version":"3.41.2"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>An 83-year-old male presented to our Digestive System Department with a 5-day history of severe gastrointestinal (GI) bleeding and a 14-year history of idiopathic thrombocytopenic purpura (ITP) with low platelet levels. Colonoscopy revealed extensive telangiectasias throughout the colon, particularly in the transverse and ascending segments. Standard treatment with proton-pump inhibitors and somatostatin proved ineffective. Additionally, conventional therapies such as estrogen and thalidomide were contraindicated due to the comorbidity of ITP. Endoscopic hemostasis was also difficult to perform because of the widespread nature of the lesions. However, after the innovative use of four courses of recombinant human vascular endostatin (Endostar) therapy, the colon telangiectasia was completely resolved, and the patient reported no GI bleeding for 2\u202fyears. Managing severe GI bleeding with a rare etiology is particularly challenging, especially in patients with contraindications to conventional treatments due to comorbidities. In this case, a vascular endothelial growth factor (VEGF) inhibitor was successfully applied to treat a refractory and rare GI bleeding, which may offer a novel therapeutic approach for similar cases.<\/jats:p>","DOI":"10.3389\/fmed.2024.1511513","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T06:10:46Z","timestamp":1736921446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Successful therapy with recombinant human vascular endostatin in an elderly man with colon telangiectasia and idiopathic thrombocytopenic purpura"],"prefix":"10.3389","volume":"11","author":[{"given":"Yushan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongbin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingshan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11033-020-06108-9","article-title":"Understanding angiogenesis and the role of angiogenic growth factors in the vascularisation of engineered tissues","volume":"48","author":"Omorphos","year":"2021","journal-title":"Mol Biol Rep"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/j.1572-0241.1999.01017.x","article-title":"Increased expression of angiogenic factors in human colonic angiodysplasia","volume":"94","author":"Junquera","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejim.2023.05.020","article-title":"Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases","volume":"115","author":"Villanueva","year":"2023","journal-title":"Eur J Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1053\/gast.2001.28650","article-title":"A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia","volume":"121","author":"Junquera","year":"2001","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2303706","article-title":"Thalidomide for recurrent bleeding due to small-intestinal Angiodysplasia","volume":"389","author":"Chen","year":"2023","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1572-0241.2007.01053.x","article-title":"Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia","volume":"102","author":"Junquera","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al-Samkari","year":"2019","journal-title":"J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12032-023-02245-w","article-title":"Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status","volume":"41","author":"Anakha","year":"2023","journal-title":"Med Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s13205-023-03719-4","article-title":"Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis. 3","volume":"13","author":"Vimalraj","year":"2023","journal-title":"Biotech"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"13317","DOI":"10.3390\/ijms241713317","article-title":"Vascular endothelial growth factor-D (VEGF-D): an angiogenesis bypass in malignant tumors","volume":"24","author":"Bokhari","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor a","volume":"24","author":"P\u00e9rez-Guti\u00e9rrez","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"15330338211064434","DOI":"10.1177\/15330338211064434","article-title":"Tolerance and pharmacokinetics of recombinant human Endostatin administered as single-dose or multiple-dose infusions in patients with advanced solid tumors: a phase I clinical trial","volume":"20","author":"Wang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ajg.2014.391","article-title":"Long-term therapy with bevacizumab in a patient with Glanzmann\u2019s thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions","volume":"110","author":"Marlu","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"36716","DOI":"10.18632\/oncotarget.13545","article-title":"Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV","volume":"8","author":"Xing","year":"2017","journal-title":"Oncotarget"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"11306","DOI":"10.1073\/pnas.1203275109","article-title":"Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition","volume":"109","author":"Sunshine","year":"2012","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1511513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T06:10:52Z","timestamp":1736921452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1511513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":19,"alternative-id":["10.3389\/fmed.2024.1511513"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1511513","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"article-number":"1511513"}}